I

Innate Pharma SA
D

IPHA

1.87000
USD
-0.08
(-4.10%)
مفتوح الان
حجم التداول
1,500
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
172,335,082
أصول ذات صلة
A
ADMA
-0.520
(-2.50%)
20.290 USD
A
AKBA
0.06000
(1.69%)
3.61500 USD
A
ARDX
0.01000
(0.28%)
3.59500 USD
B
BCRX
-0.170
(-1.64%)
10.190 USD
F
FGEN
-0.00560
(-2.09%)
0.26190 USD
INSM
INSM
1.890
(1.91%)
100.650 USD
K
KPTI
0.01000
(0.22%)
4.47000 USD
M
MDGL
-6.92
(-2.34%)
288.87 USD
X
XNCR
-0.17100
(-1.87%)
8.99000 USD
المزيد
الأخبار المقالات

العنوان: Innate Pharma SA

القطاع: Healthcare
الصناعة: Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.